Dr Jiri Pavlu is a Consultant Haematologist at Hammersmith Hospital and Honorary Clinical Senior Lecturer at Imperial College London. He is the clinical lead for acute leukaemia and myelodysplastic syndromes at Imperial College Healthcare.
He is active in clinical research and uses the latest drugs and treatments to offer highly personalised care. His scientific research focuses acute leukaemia and on improvements in the safety and patient outcomes of transplantation. He is an active member of the acute leukaemia working parties in both the National Cancer Research Institute and the European Bone Marrow Transplantation Society (EBMT). He is also an accredited transplantation quality assurance inspector (Joint Accreditation Committee – International Society for Cellular Therapy & EBMT).
et al., 2023, Current use of fecal microbiota transfer in patients with hematologic diseases: a survey on behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT., Bone Marrow Transplant, Vol:58, Pages:1419-1421
et al., 2023, Current use of fecal microbiota transfer in patients with hematologic diseases: a survey on behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT, Bone Marrow Transplantation, ISSN:0268-3369
et al., 2023, Thiotepa-busulfan-fludarabine compared to treosulfan-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with acute myeloid leukemia in remission: a study from the acute leukemia working party of the EBMT, Hemasphere, Vol:7, ISSN:2572-9241
et al., 2023, Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT (16, 58, 2023), Journal of Hematology & Oncology, Vol:16
et al., 2023, Urinary tract infections in HSCT: how big is the problem?, OXFORD UNIV PRESS